Therapy Areas: Infectious Diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
16 October 2024 - Biopharmaceutical company GSK PLC (LSE: GSK) (NYSE: GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for gepotid...
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
14 October 2024 - Specialty biopharmaceutical company RedHill Biopharma Ltd. (Nasdaq:RDHL) announced on Monday that the Biomedical Advanced Research and Development Authority (BARDA) selected its drug...
Seegene finalises Werfen partnership agreement
9 October 2024 - Seegene Inc, a South Korean provider of solutions for PCR molecular diagnostics, announced on Tuesday that it has finalised a technology-sharing partnership agreement with Spanish dia...
hVIVO reports positive results from RSV antiviral human challenge trial
7 October 2024 - hVIVO plc (AIM: HVO), a specialist contract research organisation (CRO) in infectious disease testing, has announced positive topline results from a Phase 2a Respiratory Syncytial Vir...
Gilead expands global access to lenacapavir for HIV prevention
2 October 2024 - HIV medication company Gilead Sciences Inc (Nasdaq: GILD) announced on Wednesday that it has signed royalty-free voluntary licensing agreements with six generic manufacturers to incre...
Lunaphore partners with Discovery Life Sciences
27 September 2024 - US life sciences company Bio-Techne Corporation (NASDAQ: TECH) announced on Thursday that its spatial biology brand, Lunaphore, is partnering with Discovery Life Sciences (Discover...